



(11) **EP 1 971 338 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 84

(48) Corrigendum issued on:
21.09.2011 Bulletin 2011/38

(45) Date of publication and mention
of the grant of the patent:
09.03.2011 Bulletin 2011/10

(21) Application number: **06820566.5**

(22) Date of filing: **19.12.2006**

(51) Int Cl.:
A61K 31/517^(2006.01) A61K 31/519^(2006.01)
A61P 35/00^(2006.01)

(86) International application number:
PCT/GB2006/004750

(87) International publication number:
WO 2007/071958 (28.06.2007 Gazette 2007/26)

(54) **COMBINATION OF ZD6474 AND PEMETREXED**
KOMBINATION VON ZD6474 UND PEMETREXED
COMBINAISON DE ZD6474 ET DE PEMETREXED

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR
Designated Extension States:
HR

(30) Priority: **22.12.2005 GB 0526121**
31.05.2006 GB 0610706

(43) Date of publication of application:
24.09.2008 Bulletin 2008/39

(73) Proprietor: **AstraZeneca AB**
151 85 Södertälje (SE)

(72) Inventors:
• **WEDGE, Stephen, Robert**
Cheshire SK10 4TG (GB)
• **RYAN, Anderson, Joseph**
Cheshire SK10 4TG (GB)

(56) References cited:

- **HUBER PETER E ET AL: "Trimodal cancer treatment: Beneficial effects of combined antiangiogenesis, radiation, and chemotherapy" CANCER RESEARCH, vol. 65, no. 9, May 2005 (2005-05), pages 3643-3655,3633, XP002464232 ISSN: 0008-5472**
- **BISCHOF M ET AL: "Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells" INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, US, vol. 60, no. 4, 15 November 2004 (2004-11-15), pages 1220-1232, XP004618608 ISSN: 0360-3016**
- **GLADE-BENDER J ET AL: "VEGF BLOCKING THERAPY IN THE TREATMENT OF CANCER" EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 2, April 2003 (2003-04), pages 263-276, XP009060849 ISSN: 1471-2598**
- **SRIDHAR SRIKALA S ET AL: "Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer." LUNG CANCER (AMSTERDAM, NETHERLANDS) DEC 2003, vol. 42 Suppl 1, December 2003 (2003-12), pages S81-S91, XP002464233 ISSN: 0169-5002**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 971 338 B8